Arrowhead Pharmaceuticals, Inc.
NEWS
ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.
Arrowhead will conduct its activities through preclinical development stages, while Horizon will have sole responsibility for the clinical development and commercialization of the medicine.
The investigational drug, ARO-AAT, is a potential first-in-class treatment that reduces the generation of mutant alpha-1 antitrypsin protein (Z-AAT), the primary contributor to liver disease progression in patients with AATLD.
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Christopher Anzalone, Arrowhead’s chief executive officer, took time to speak with BioSpace about the company’s large pipeline and why they’re so excited about 2020.
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week’s appointments.
Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.
Two pharmaceutical companies and a medtech maker snagged three of the top-10 spots on Deloitte’s 2018 North America Technology Fast 500, a ranking of the fastest-growing North American companies in the fields of technology, life sciences, telecommunications, media and energy.
Arrowhead announced a deal with Johnson & Johnson that could conceivably be worth over $3.7 billion, with J&J agreeing to pick up a minor stake in the company, including the task of cultivating and promoting its ARO-HBV Hepatitis B drug.
JOBS
IN THE PRESS